CapGenesis submits orphan drug designation requests in US and Europe for CGS-200
CGS-200 is a novel high-strength topical formulation of the TRPV1 channel agonist trans-capsaicin combined with hyaluronic acid. It has been designed to deliver long-term desensitization of nerve fibers
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.